IMMUNE RESPONSES TO MRNA VACCINES AGAINST SARS-COV2 IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES

被引：0

作者：

Sieiro Santos, C. ^{[1
]}

Moriano, C. ^{[1
]}

Diez Alvarez, E. ^{[1
]}

Calleja Antolin, S. ^{[2
]}

Gonzalez Fernandez, I. ^{[1
]}

Alvarez Castro, C. ^{[1
]}

Ruiz de Morales, J. M. Garcia ^{[2
]}

机构：

[1] Complejo Asistencial Univ Leon, Rheumatol, Leon, Spain

[2] Complejo Asistencial Univ Leon, Immunol, Leon, Spain

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷

关键词：

D O I：

10.1136/annrheumdis-2022-eular.13

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS1191

引用

页码：923 / 923

页数：1

共 3 条

[1] Contributions of humoral and cellular immunity to vaccine-induced protection in humans [J].

Amanna, Ian J. ;

Slifka, Mark K. .

VIROLOGY, 2011, 411 (02) :206-215

[2] The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab [J].

Arad, U. ;

Tzadok, S. ;

Amir, S. ;

Mandelboim, M. ;

Mendelson, E. ;

Wigler, I. ;

Sarbagil-Maman, H. ;

Paran, D. ;

Caspi, D. ;

Elkayam, O. .

VACCINE, 2011, 29 (08) :1643-1648

[3] Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases [J].

Spiera, Robert ;

Jinich, Sarah ;

Jannat-Khah, Deanna .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (10) :1357-+

← 1 →